Differential Activity of PARP Inhibitors in
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
02
2021
revised:
22
04
2021
accepted:
11
06
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration-approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with A total of 123 patients (13 PARP inhibitor efficacy is diminished in
Identifiants
pubmed: 34778690
doi: 10.1200/PO.21.00070
pii: PO.21.00070
pmc: PMC8575434
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097186
Pays : United States
Informations de copyright
© 2021 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
Emmanuel S. Antonarakis Honoraria: Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology Consulting or Advisory Role: Sanofi, Dendreon, Janssen Biotech, ESSA, Merck, AstraZeneca, Clovis Oncology, Lilly, Bayer Research Funding: Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Astellas Pharma, Tokai Pharmaceuticals, Merck, AstraZeneca, Clovis Oncology, Constellation Pharmaceuticals Patents, Royalties, Other Intellectual Property: Coinventor of a biomarker technology that has been licensed to Qiagen Travel, Accommodations, Expenses: Sanofi, Dendreon, Medivation No other potential conflicts of interest were reported. Emmanuel S. Antonarakis Honoraria: Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology Consulting or Advisory Role: Sanofi, Dendreon, Janssen Biotech, ESSA, Merck, AstraZeneca, Clovis Oncology, Lilly, Bayer Research Funding: Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Astellas Pharma, Tokai Pharmaceuticals, Merck, AstraZeneca, Clovis Oncology, Constellation Pharmaceuticals Patents, Royalties, Other Intellectual Property: Coinventor of a biomarker technology that has been licensed to Qiagen Travel, Accommodations, Expenses: Sanofi, Dendreon, Medivation No other potential conflicts of interest were reported.
Références
Nat Rev Clin Oncol. 2020 Aug;17(8):455-456
pubmed: 32447344
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Oncologist. 2016 Aug;21(8):940-5
pubmed: 27317574
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
JCO Precis Oncol. 2019;3:
pubmed: 31218271
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
Nat Rev Urol. 2019 Jan;16(1):4-6
pubmed: 30498248
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Ann Oncol. 2017 Jul 1;28(7):1495-1507
pubmed: 28383660
N Engl J Med. 2020 Jul 16;383(3):286-288
pubmed: 32668122
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
Eur Urol. 2020 Nov;78(5):652-656
pubmed: 32624276
JCO Precis Oncol. 2020;4:442-465
pubmed: 32903788
J Clin Oncol. 2020 Nov 10;38(32):3735-3739
pubmed: 32870734
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Cancer Discov. 2020 Oct;10(10):1475-1488
pubmed: 32699032
Eur Urol Oncol. 2020 Oct;3(5):594-611
pubmed: 32814685
J Clin Invest. 2020 Apr 1;130(4):1743-1751
pubmed: 31874108
Eur Urol. 2019 Oct;76(4):452-458
pubmed: 30797618
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Clin Cancer Res. 2018 Nov 15;24(22):5585-5593
pubmed: 30068710